Detalhe da pesquisa
1.
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer.
Proc Natl Acad Sci U S A
; 116(52): 26823-26834, 2019 Dec 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31826955
2.
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.
Proc Natl Acad Sci U S A
; 113(43): E6600-E6609, 2016 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-27791031
3.
High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer.
Cell Rep
; 42(8): 112821, 2023 Aug 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37467106
4.
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models.
NPJ Breast Cancer
; 7(1): 63, 2021 May 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34045483
5.
Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
Clin Cancer Res
; 27(17): 4870-4882, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33536276
6.
Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer.
Mol Cancer Res
; 17(11): 2318-2330, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31420371
7.
Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
Clin Cancer Res
; 27(17): 4939, 2021 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34470810